接受化/生物放疗的头颈癌患者中肿瘤相关巨噬细胞及HLA I类表达根据HPV状态的影响
研究纳入95例接受顺铂化放疗(CRT)或西妥昔单抗生物放疗(BRT)的头颈鳞癌患者,半定量评估上皮内及间质CD68+、CD68+CD163+巨噬细胞密度和肿瘤细胞HLA I类表达。多因素分析显示上皮内巨噬细胞密度(IEMD)为无进展生存(PFS)的预后因素,总生存(OS)仅呈非显著改善趋势;HLA I类下调非独立预后因素。p16+患者中高IEMD者5年PFS优于低IEMD者(81.2% vs 25.0%,p<0.001),p16-者无差异;低间质M2密度者CRT较BRT的5年PFS显著改善(54.5% vs 36.1%,p=0.03),高M2者无显著差异(50.3% vs 42.9%,p=0.67)。作者认为TAM表型与分布的预后作用取决于HPV状态,可能预测治疗反应,并提示需在前瞻性研究中进一步验证。
要点
- 上皮内巨噬细胞密度(IEMD)是多因素分析中PFS的预后因素,OS仅呈非显著改善趋势。
- p16+患者中高IEMD者5年PFS 81.2% vs 低IEMD者25.0%(p<0.001),p16-者无差异。
- 低间质M2密度者CRT较BRT的5年PFS改善(54.5% vs 36.1%,p=0.03),高M2者无显著差异。
核心结论
- TAM表型与分布的预后作用取决于HPV状态,可能预测治疗反应。
- 作者提示需在前瞻性研究中进一步验证。
研究设计与样本
- 研究纳入95例接受根治性放疗联合顺铂(CRT)或西妥昔单抗(BRT)的头颈鳞状细胞癌患者。
- 半定量评估上皮内CD68+细胞、间质CD68+CD163+细胞(M2)密度及肿瘤细胞HLA I类表达,分析生物标志物与治疗结局的相关性。
主要发现
- 多因素分析显示上皮内巨噬细胞密度(IEMD)为有利无进展生存(PFS)的预后因素,总生存(OS)仅呈非显著改善趋势。
- HLA I类下调不是独立预后因素。
- p16+人群中高IEMD者5年PFS 81.2% vs 低IEMD者25.0%(p<0.001),p16-人群中未观察到差异。
- 按原发肿瘤部位分层,IEMD在口咽癌(OPC)患者中有预后价值,非OPC患者中无。
- 低间质M2密度者CRT较BRT的5年PFS显著改善(54.5% vs 36.1%,p=0.03),高M2者无显著差异(50.3% vs 42.9%,p=0.67)。
关键数值与推荐
- p16+人群高IEMD者5年PFS 81.2% vs 低IEMD者25.0%(p<0.001)。
- 低间质M2密度者CRT 5年PFS 54.5% vs BRT 36.1%(p=0.03)。
- 高间质M2密度者CRT 5年PFS 50.3% vs BRT 42.9%(p=0.67)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者提示需在前瞻性研究中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To investigate the prognostic value of tumor-associated macrophages (TAM) and HLA class I expression according to HPV status in patients with head and neck squamous cell carcinoma treated with definitive radiotherapy combining cisplatin (CRT) or cetuximab (BRT). MATERIAL AND METHODS: Ninety-five patients were enrolled. The density of CD68+ cells and CD68+ CD163+ cells (further referred as M2) in the intraepithelial and the stromal compartments, respectively, as well as HLA class I expression in tumor cells, were evaluated semi-quantitatively. Correlations between biomarker expression and treatment outcomes were analyzed. RESULTS: Multivariate analysis showed that the intraepithelial macrophage density (IEMD) was prognostic for favorable progression-free survival (PFS) and there was a non-significant trend for improved overall survival (OS). HLA class I down-regulation was not an independent prognostic factor. Subgroup analysis showed that in p16+ population, patients with high IEMD had improved 5-year PFS vs. patients with low IEMD (81.2% vs. 25.0%, p < 0.001), while in p16- population, no difference was observed. Similarly, when stratified by primary tumor site, IEMD showed prognostic value in oropharyngeal cancer patients (OPC) but not non-OPC patients. Five-year PFS of patients with low stromal M2 macrophage density treated with CRT was significantly improved vs. those with BRT (54.5% vs. 36.1%, p = 0.03), while in tumors with high M2, there was no significant difference (50.3% vs. 42.9%, p = 0.67). CONCLUSIONS: The prognostic role of TAM phenotype and distribution depends on HPV status and might predict treatment response. They prompt further validation in prospective studies.
引用
- Ou D, Adam J, Garberis I, et al. Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy. Radiother Oncol. 2018. PMID: 30172455. doi:10.1016/j.radonc.2018.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。